S9, a Novel Anticancer Agent, Exerts Its Anti-Proliferative Activity by Interfering with Both PI3K-Akt-mTOR Signaling and Microtubule Cytoskeleton
Chao Zhang, Na Yang, Chun-hao Yang et al. · 2009
Read S9, a Novel Anticancer Agent, Exerts Its Anti-Proliferative Activity by Interfering with Both PI3K-Akt-mTOR Signaling and Microtubule Cytoskeleton by Chao Zhang, Na Yang, Chun-hao Yang et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0004881.txt.
Description
Chao Zhang and colleagues reported S9, a novel anticancer agent interfering with PI3K Akt mTOR signaling and microtubules, in PLOS ONE in 2009. Deregulation of the PI3K Akt mTOR pathway plays central roles in tumor formation and progression, providing validated therapy targets. S9, a hybrid of lactone and indole compounds, exerts anti proliferative activity by simultaneously disrupting signaling and the microtubule cytoskeleton in cancer cell models.
Dual action may delay resistance emergence. Hybrid design merges two pharmacophores productively. Cell division and growth signals fall together. Further growth requires animal testing. Taken together, the findings mark a useful step for research in this area. The team also set out clear next steps for work in this field. More tests with more samples will help show how strong the effect is.
Catalog record
| CREATOR | Chao Zhang, Na Yang, Chun-hao Yang et al. |
|---|---|
| YEAR | 2009 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0004881